Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473824 · ClinicalTrials.gov registry record · Phase 2
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
A Phase 2 study, sponsored by ADMA Biologics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00473824 is a Phase 2 study that was terminated before completion, run by ADMA Biologics. The registered enrollment target is 7 participants.
The verdict
NCT00473824, a Phase 2 study, was terminated before completion, sponsored by ADMA Biologics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) \[Civacir(TM)\] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
Interventions
- BIOLOGICAL Hepatitis C Immune Globulin Intravenous (Human) 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473824
The ClinicalTrials.gov registry entry for NCT00473824 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ADMA Biologics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hepatitis C Immune Globulin Intravenous (Human) 5% is the first listed.
NCT00473824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00473824 about?
NCT00473824 is a clinical study titled "Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation". A Phase 2 study to evaluate safety, pharmacokinetics and efficacy of Hepatitis C Immune Globulin Intravenous (human) \[Civacir(TM)\] for preventing or reducing the impact of recurrent HCV infection following liver transplantation.
What is the current status of trial NCT00473824?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-05. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00473824?
The interventions under investigation include: Hepatitis C Immune Globulin Intravenous (Human) 5% (BIOLOGICAL).
Who is sponsoring clinical trial NCT00473824?
This trial is sponsored by ADMA Biologics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.